IMV Inc. Celebrates Grand Opening of New Facility in Dartmouth, Nova Scotia
September 04 2018 - 5:50PM
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, celebrated its grand opening today of its new
facilities in Dartmouth, Nova Scotia. Frederic Ors, IMV’s Chief
Executive Officer, and Andrew Sheldon, IMV’s Chairman of the Board,
opened today’s event with remarks about the company’s milestones
and successes. Other speakers included federal MP Darren Fisher,
the Honourable Randy Delorey, Minister of Health and Wellness, and
Dartmouth Centre Councillor Sam Austin. Emilie Chiasson, the
Atlantic Regional Director of Ovarian Cancer Canada, served as the
event’s Master of Ceremonies.
“The opening of our new facility marks another successful stage
of growth for IMV, which will enable us to accelerate and expand on
our ambitious research and clinical development programs,” said
Frederic Ors. “We are focused on attracting and retaining the
best employees for a clear purpose: to develop breakthrough
immunotherapies for individuals living with serious medical
conditions such as ovarian and lymphoma cancers. We look
forward to continuing our growth with the strong support of the
local community in Nova Scotia.”
The Company moved from its offices and laboratories located in
the Innovacorp Enterprise Centre on Summer Street, Halifax, to the
Bluefrog Business Campus in Dartmouth to accommodate the growing
business. The new space features upgraded facilities and equipment
as well as increased laboratory size and capacity. IMV has now
nearly tripled its space to allow for expanding business and
operations in the coming years.
“IMV is providing high-quality jobs for our region’s educated
workforce, helping to attract and retain talent. It is also drawing
international attention to the work that is being done within the
life sciences community in Nova Scotia,” says Darren Fisher, Member
of Parliament for Dartmouth-Cole Harbour, on behalf of the
Honourable Navdeep Bains, Minister of Innovation, Science and
Economic Development and Minister responsible for Atlantic Canada
Opportunities Agency (ACOA). “This kind of recognition, combined
with business successes such as becoming a publicly traded company
on the TSX and Nasdaq, has helped to bring significant investment
to the area. This is why the Government of Canada, through the
ACOA, has been a proud supporter since the get-go, assisting with
funding for research and development, patent protection, and
bringing the Company’s product candidates to market.”
About IMV
IMV Inc., formerly Immunovaccine Inc., is a clinical stage
biopharmaceutical company dedicated to making immunotherapy more
effective, more broadly applicable, and more widely available to
people facing cancer and other serious diseases. IMV is pioneering
a new class of immunotherapies based on the Company’s proprietary
drug delivery platform. This patented technology leverages a novel
mechanism of action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a
T cell-activating immunotherapy that combines the utility of the
platform with a target: surviving. IMV is currently assessing
DPX-Survivac as a combination therapy in multiple clinical studies
with Incyte and Merck. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no responsibility to
update forward-looking statements in this press release except as
required by law.
Contacts for
IMV:MEDIA Mike Beyer, Sam
Brown Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/1b59b9b0-072e-4428-a03f-42605483f01b
IMV (TSX:IMV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IMV (TSX:IMV)
Historical Stock Chart
From Sep 2023 to Sep 2024